In short
Tinengotinib, also known as TT-00420, is an investigational drug currently being studied in clinical trials for the treatment of various advanced solid tumors, with a particular focus on cholangiocarcinoma (bile duct cancer). These trials aim to evaluate the safety, efficacy, and potential benefits of Tinengotinib in patients who have not responded well to previous treatments. The ongoing research explores its use as a standalone therapy and in combination with other cancer treatments, offering hope for patients with limited treatment options.
At a glance
- Drug Name
- Tinengotinib (TT-00420)
- Primary Conditions Studied
- Advanced Solid Tumors, Cholangiocarcinoma, Prostate Cancer
- Administration
- Oral tablet, typically once daily
- Dosages Studied
- 8 mg and 10 mg daily doses
- Trial Phases
- Phase II and Phase III
- Key Outcomes Measured
- Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), Safety and Tolerability
- Combination Therapies
- Studied with abiraterone acetate/prednisone and enzalutamide for prostate cancer
- Patient Population
- Adults with advanced solid tumors, focus on those who failed or relapsed after chemotherapy and FGFR inhibitor treatment
What is Tinengotinib?
Tinengotinib, also known by its research code TT-00420, is a new drug being studied for the treatment of various advanced cancers. It is currently undergoing clinical trials to evaluate its safety and effectiveness in patients who have not responded well to other treatments.
What Conditions Does Tinengotinib Treat?
Tinengotinib is being investigated for the treatment of several types of cancer, including:
- Advanced solid tumors: These are cancers that form solid masses in the body and have spread or become difficult to treat with standard therapies.
- Cholangiocarcinoma: This is a rare type of cancer that starts in the bile ducts, which are tubes that connect the liver, gallbladder, and small intestine.
- Metastatic castration-resistant prostate cancer (mCRPC): This is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy.
How Does Tinengotinib Work?
While the exact mechanism of action is not fully described in the provided information, Tinengotinib appears to target specific pathways involved in cancer growth. It is being studied in patients who have not responded well to other treatments, including chemotherapy and drugs that target a protein called FGFR (Fibroblast Growth Factor Receptor). This suggests that Tinengotinib may work differently from existing therapies, potentially offering a new option for patients with limited treatment choices.
Current Clinical Trials
Several clinical trials are currently underway to evaluate Tinengotinib:
- Rollover Study: This study allows patients who have benefited from Tinengotinib in previous trials to continue receiving the drug.
- Phase II Study in Cholangiocarcinoma: This trial is testing Tinengotinib in patients with cholangiocarcinoma who have not responded to chemotherapy and FGFR inhibitors.
- Phase Ib/II Study in Prostate Cancer: This study is evaluating Tinengotinib in combination with other drugs for the treatment of metastatic castration-resistant prostate cancer.
- Phase III Study in Cholangiocarcinoma: This large-scale trial is comparing Tinengotinib to standard treatments in patients with cholangiocarcinoma who have specific genetic alterations (FGFR-altered).
How is Tinengotinib Administered?
Tinengotinib is taken orally as a tablet. The dosage and frequency may vary depending on the specific trial and patient needs. Some common dosages being studied include:
- 10 mg once daily
- 8 mg once daily
The medication is typically taken in cycles, with each cycle lasting 21 or 28 days.
Potential Side Effects
As Tinengotinib is still in clinical trials, the full range of potential side effects is not yet known. The trials are closely monitoring patients for any adverse events (side effects). These are categorized based on their severity using a standardized system called the Common Terminology Criteria for Adverse Events (CTCAE).
Patients participating in clinical trials are carefully monitored for any side effects, and the dosage may be adjusted if necessary to ensure safety and tolerability.
Future Prospects
The ongoing clinical trials aim to determine several important aspects of Tinengotinib's performance, including:
- Objective Response Rate (ORR): This measures how many patients experience a significant reduction in tumor size.
- Progression-Free Survival (PFS): This evaluates how long patients live without their cancer getting worse.
- Overall Survival (OS): This measures how long patients live after starting treatment.
- Duration of Response (DOR): This assesses how long the cancer remains controlled in patients who respond to the treatment.
If these trials show positive results, Tinengotinib could become an important new treatment option for patients with advanced cancers, particularly those who have not responded well to other therapies.